Sangamo Therapeutics Inc. (SGMO)

16.50
NASDAQ : Health Technology
Prev Close 16.12
Day Low/High 16.05 / 16.70
52 Wk Low/High 8.00 / 27.50
Avg Volume 2.40M
Exchange NASDAQ
Shares Outstanding 101.50M
Market Cap 1.64B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

Interesting SGMO Put And Call Options For July 20th

Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease

Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease

Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc.

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

First Week Of SGMO June 15th Options Trading

Investors in Sangamo Therapeutics Inc saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

The Market Is Finally Rewarding Stock Picking

The Market Is Finally Rewarding Stock Picking

The game plan is to spot the charts that have more room to run.

Markets Recovering From Latest Trump Tweetstorm

Markets Recovering From Latest Trump Tweetstorm

Wall Street discounting talk of bombing Syria from president.

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

2 Biotech Stocks to Consider

2 Biotech Stocks to Consider

Many stocks are already at support levels and are offering opportunities to start some positions.

Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program

Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program

Study provided proof of concept for development of SB-913 product candidate currently being evaluated in Phase 1/2 clinical trial

Why Gun-Shy Market Bulls Can't Pull the Trigger Like They Used To

Why Gun-Shy Market Bulls Can't Pull the Trigger Like They Used To

4 stocks on my shopping list for when conditions improve.

Strange: Bullish SGMO Analysts Actually See -8.91% Downside

Strange: Bullish SGMO Analysts Actually See -8.91% Downside

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Sangamo Therapeutics Inc . The average 12-month price target for SGMO — averaging the work of 6 analysts — reveals an average price target of $23.50/share.

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

Kite, A Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

Kite, A Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology --

Biotech Gold Rush Starts to Pick Up; Xerox, Fujifilm Saga Continues -- ICYMI

Biotech Gold Rush Starts to Pick Up; Xerox, Fujifilm Saga Continues -- ICYMI

Here's what you need to know now for Wednesday, Feb. 14.

Biotech Heats Up as Fear of Missing Out Returns

Biotech Heats Up as Fear of Missing Out Returns

It's hard to believe the bounce will continue to run in V-shaped fashion.

Seeing Good Action in Several Stocks, Buying More MJ, Gold

Seeing Good Action in Several Stocks, Buying More MJ, Gold

It is a very different market environment now which can be very rewarding depending on your style.

TheStreet Quant Rating: D (Sell)